Phathom Pharmaceuticals (NASDAQ: [[ticker:PHAT]]) on Monday named Martin Gilligan as its chief commercial officer. Gilligan was most recently a corporate vice president at Celgene, where he led marketing, market access, and business development for the Summit, NJ-based biopharma’s inflammation and immunology unit.
Phathom, in Florham Park, NJ, is in late-stage development of vonoprazan—an acid blocker whose US, European, and Canadian rights it licensed from Takeda (NYSE: [[ticker:TAK]])—to treat gastroesophageal reflux disease (GERD) and, in combination with antibiotics, H. pylori infection.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
